C12N 2510/04
Immortalised cells
C12N2510/04 (Immortalised cells) appears on 389 US grants and 580 published applications in this corpus.
Search patents in C12N- Granted patents
- 389
- Published applications
- 580
- Assignees
- 338
- Inventors
- 1,196
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 6 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 17 | 0 |
| 1998 | 29 | 0 |
| 1999 | 24 | 0 |
| 2000 | 14 | 0 |
| 2001 | 18 | 9 |
| 2002 | 17 | 36 |
| 2003 | 17 | 49 |
| 2004 | 6 | 27 |
| 2005 | 12 | 38 |
| 2006 | 10 | 21 |
| 2007 | 11 | 24 |
| 2008 | 14 | 13 |
| 2009 | 5 | 24 |
| 2010 | 13 | 17 |
| 2011 | 16 | 19 |
| 2012 | 12 | 22 |
| 2013 | 6 | 10 |
| 2014 | 13 | 26 |
| 2015 | 13 | 23 |
| 2016 | 18 | 20 |
| 2017 | 14 | 11 |
| 2018 | 8 | 18 |
| 2019 | 12 | 18 |
| 2020 | 7 | 18 |
| 2021 | 5 | 16 |
| 2022 | 7 | 23 |
| 2023 | 9 | 17 |
| 2024 | 7 | 24 |
| 2025 | 10 | 24 |
| 2026 | 2 | 33 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Three-dimensional culture of immortalized skin cells on the superficial layer of which a stratum corneum is formed, method for producing said three-dimensional culture, and method for evaluating test substance using said three-dimensional culture7 Jul 2026US 12,674,135 B2National Institute of Advanced Industrial Science and Technology
- Product, system and method of cell cultivation30 Jun 2026US 12,668,774 B2BTL Healthcare Technologies A.S.
- Methods of using Zscan4 for rejuvenating human cells25 Nov 2025US 12,478,657 B2Elixirgen Therapeutics, Inc.
- Methods of using ZSCAN4 for rejuvenating human cells25 Nov 2025US 12,478,659 B2Elixirgen Therapeutics, Inc.
- Expansion of natural killer and chimeric antigen receptor-modified cells28 Oct 2025US 12,453,773 B2Houston Methodist Hospital
- Kinetically controlled methods to prepare concentrated shelf-stable nucleic acid transfection vehicles8 Oct 2026US 2026/0308631 A1The Johns Hopkins University
- Nf2-associated meningioma model24 Sep 2026US 2026/0286314 A1
- Immortalization of amnion-derived multipotent progenitor cell and uses thereof17 Sep 2026US 2026/0275276 A1Noveome Biotherapeutics, Inc.
- Methods for Preparing and Storing Immortalized Cytolytic Natural Killer Cells17 Sep 2026US 2026/0275301 A1ImmunityBio, Inc.
- Production cell lines with targeted integration sites17 Sep 2026US 2026/0275373 A1Seagen Inc.
Most cited
By later US patents
- Control of cell growth in a bioartificial organ with extracellular matrix coated microcarriers151US 5,858,747 ACytoTherapeutics, Inc. · 1999
- Conditioned media for propagating human pluripotent stem cells145US 6,642,048 B2Geron Corporation · 2003
- Therapy and diagnosis of conditions related to telomere length and/or telomerase activity143US 5,489,508 AUniversity of Texas System Board of Regents · 1996
- Medium for growing human embryonic stem cells127US 7,297,539 B2Geron Corporation · 2007
- Embryonic cell populations and methods to isolate such populations111US 5,914,268 ANational Jewish Center for Immunology and Respiratory Medicine · 1999